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Abstracts A23
Endogeneity was controlled by addition of a generalized residual function, constructed
using Lee’s (1983) approach for non-normal polychotomous choice models. Hypoth-
esis testing was based on cluster-bootstrapped errors. RESULTS: Controlling endoge-
neity signiﬁ cantly increased ATE1 for adalimumab, while decreasing ATE1 for
etanercept, compared to naïve ﬁ xed-effects model. ATE1 estimate from the nested-logit 
selection model based correction was lower as compared to multinomial-logit. When 
heterogeneity in parameters was allowed, ATE of adalimumab was no longer statisti-
cally signiﬁ cant under the nested-logit corrected model (ATE  $160,108, p  0.43).
ATE for etanercept ($17,466, p  0.93) was no longer statistically signiﬁ cant under
either of the endogeneity corrected models. Based on likelihood-ratio test for the
selection model, and t-test for time-varying endogeneity, the appropriate model was 
the nested-logit based endogeneity corrected ﬁ xed-effects model. CONCLUSIONS:
Random assignment of patients currently on standard DMARD treatment to either
adalimumab or etanercept may not cause a signiﬁ cant difference in quarterly expen-
diture, if treatment effects are heterogeneous and treatment decision are based on these 
individual gains.
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OBJECTIVES: To estimate the impact of varying selection bias correction techniques
on the average treatment effect. The structural parameters, heterogeneous (ATE), 
and homogenous (ATE1) average treatment effects were deﬁ ned as the impact of 
treatment on total quarterly expenditure, if patients are randomly assigned to biologic 
disease modifying anti-rheumatoid drugs (DMARDs). METHODS: Retrospective
cohorts were constructed from California Medicaid paid claims from January 1, 1999 
to December 31, 2005. Non-overlapping quarters were created from pharmacy
claims for biologic (adalimumab and etanercept) and standard (leﬂ uonomide, 
hydroxychloroquine and sulfasalazine) DMARDs. Final sample included 24,504 epi-
sodes on 5,510 patients. In the two-stage estimation, the treatment selection model 
was estimated by multinomial-logit. The outcome model was ﬁ xed-effects correlated 
random coefﬁ cients model (Wooldridge-2005), allowing parameter heterogeneity. A 
generalized residual function constructed based on four different bias-correction tech-
niques for the multinomial-logit selection model namely, Lee’s (1983) (LEE), Dubin
and MacFadden’s (1984) (DMF) and two variants of Dahl’s (2002) approach (squared
(DHL1) and quadratic (DHL2) series expansions without interactions); controlled 
endogeneity in treatment choice. The generalized residual was regressed on exogenous
covariates to assess multicollinearity. Hypothesis testing was based on cluster-boot-
strapped errors. RESULTS: Multicollinearity was not an issue for LEE (RSQUARE 
0.07) and DMF (RSQUARE  0.08) approaches, however, it was strong in DHL1 
(RSQUARE  0.48) and DHL2 (RSQUARE  0.62), even with six exclusion restric-
tions. Time-varying endogeneity was signiﬁ cant under all approaches. Controlling
endogeneity signiﬁ cantly increased ATE1 for adalimumab, in LEE and DMF 
approaches but decreased in magnitude in DHL1 and DHL2 as compared to naïve
ﬁ xed-effects model. When heterogeneity in parameters was allowed, ATE of adalim-
umab was signiﬁ cantly higher as compared to standard DMARDs, under all bias-
correction techniques. ATE for etanercept under LEE ($46,187, p  0.75) and DMF 
($76,393, p  0.59) was not signiﬁ cant. However, ATE for etanercept under DHL1 
($192,813, p  0.001) and DHL2 ($191,463, p  0.013) was signiﬁ cantly higher as 
compared to standard DMARDs.
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OBJECTIVES: To compare two methods of constructing control cohorts for a differ-
ence-in-difference (DID) econometric model in evaluating the impact on cost-saving 
after implementing an intervention intended to reduce variation in inpatient care for 
patients with community acquired pneumonia (CAP). METHODS: Using data from 
Ofﬁ ce of Statewide Health Planning and Development (2000 to 2006), inpatient dis-
charge records from four southern California licensed hospitals implementing the
intervention were used to identify a CAP cohort. Controls were identiﬁ ed from other
California county hospitals using two methods: 1) criteria-matching, which matched 
on hospital similarity using three criteria: total number of discharges per year, number 
of California Medicaid patients, and race; and 2) propensity score (PS) matching, 
which matched on patient baseline demographic and clinical characteristics. A DID
econometric model was applied to determine intervention impact on inpatient length
of stay (LOS). A zero-truncated negative binomial regression model was performed to 
capture the change in total LOS. The model was repeated for both criteria-matched 
and PS matched cohorts. Proxy cost per inpatient day ($2,127) was multiplied by 
the change in LOS to calculate total cost savings. RESULTS: For criteria-matched
(N  36,018), mean LOS decreased for both case (0.22 days) and controls (0.10 days)
following intervention implementation. DID results showed a decrease of 0.94 days 
per case, corresponding to $440 savings per case per year (p  0.02). Results for the 
PS-matched cohorts (N  22,570) also indicated a decrease in mean LOS for case (0.23 
days) and controls (0.18 days) following implementation. However, DID results 
revealed that these differences in LOS change were not signiﬁ cant (p  0.83). CON-
CLUSIONS: The use of different methods for constructing control cohorts in the DID
analysis signiﬁ cantly impacted the evaluation of intervention effectiveness. A PS-
matched method allowed us to control observable patient characteristics and conduct 
a more appropriate evaluation.
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OBJECTIVES: Health economics is evolving as a sub-discipline that comprises several 
key areas: (A) inﬂ uences on health other than health care, (B) what is health and its
value, (C) demand for health care, (D) supply of health care, (E) microeconomic 
evaluation, (F) market equilibrium, (G) whole-system evaluation, and (H) planning, 
budgeting, and monitoring systems, deﬁ ned in a key article by Maynard and Kanavos
(Health Economics, 9:183–190, 2000). This research evaluates the proportion of lit-
erature published within these areas across three key health economics journals. 
METHODS: All articles published in Value in Health (ViH), Health Economics (HE), 
and Journal of Health Economics (JoHE) during the year 2008 were categorised by
area and author nationality (US or non-US) based on the abstract. The number of 
publications per area was calculated and the relative proportions computed as a per-
centage. RESULTS: Within ViH the majority of the published work relates to micro-
economic evaluation (26%) or the value of health (25%), particularly quality of life
and utility development/validation. In contrast, JoHE focuses on the deﬁ nition of 
health (23%) and planning, budgeting, and monitoring activities (22%), particularly
in respect to the inﬂ uence on health of policy introduction and government regulation. 
Although the focus of HE appears to be more dispersed, a large share of the literature 
again relates to monitoring health outcomes following changes in government policy/
regulation (19%). Overall, in 2008 microeconomic evaluation attracted the most 
interest (18%) whilst whole-system evaluation and market equilibrium attracted the 
least (7% and 5%, respectively). CONCLUSIONS: The central focus of the literature 
within each of the key health economics journals differs. However, both microeco-
nomic evaluation and assessment of the effect of policies/regulations on health appears 
of major interest in general. Whole-system level evaluation has received comparatively 
little attention; such analysis could be considered important in when making health 
care-related policy decisions.
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OBJECTIVES: To identify and characterize patients with hormone resistant prostate 
cancer (HRPC) in a managed care setting using diagnosis and serial PSA test result
and a statistical algorithm. METHODS: Patients with hormone-treated prostate 
cancer were identiﬁ ed from the Ingenix database of 42 million covered lives, 
07/01/2001–12/31/2007. Patients with available PSA data were stratiﬁ ed into two
groups based on their PSA results: known HRPC  1 or not known HRPC  0. A
prediction model using logistic regression to model known HRPC status as a function
of baseline clinical, demographic, utilization and expenditure measures identiﬁ able in 
claims data was utilized. The parameter estimates from the logistic model were then
applied to the entire hormone-treated population, including those without PSA data,
and predicted values (propensity scores) were obtained for all subjects. A threshold 
propensity score value for HRPC cases using sensitivity and speciﬁ city measures was 
established. RESULTS: A total of 15,353 patients with hormone treated prostate
cancer were identiﬁ ed during the study period. Based on PSA results 349 of those were
known HRPC and 625 patients were not HRPC. The remaining 14,379 patients did 
not have sufﬁ cient PSA data and were classiﬁ ed as unknown HRPC status. With the
prediction model, an additional 2,350 patients were classiﬁ ed as meeting the threshold 
propensity score value of 0.32 (sensitivity  0.76, speciﬁ city  0.73) in addition to the 
349 true cases totaling 2,699 HRPC patients. The demographic, clinical, utilization
and expenditure characteristics of the known HRPC sample and those identiﬁ ed using 
the prediction model were highly comparable. CONCLUSIONS: In the absence of 
PSA test results, a prediction model utilizing other claims-based measures may be used 
to identify possible HRPC patients.
